On an immunostimulant - Advaxis (ADXS.OB)/Listeria monocytogenes
A Cancer Vaccine Based on Dairy Products May Stop and Eradicate Cancers
PRINCETON, N.J., Dec. 5 /PRNewswire/ -- A scientist and her team of
researchers appear to have made a giant step in the development of a series of
effective cancer-fighting vaccines that appear to be able to stop and reverse
cancer growth.
Central to this discovery is the microbe Listeria monocytogenes, a
bacterium found in milk, cheese and other dairy products. This common
microorganism apparently aids in fighting cancer by activating the body's own
killer cells (cytotoxic T cells) to bring out a stronger immune response to
the presence of cancer cells.
In a scientific study published in the Journal of Immunology (Sept. 2005),
Yvonne Paterson, Ph.D., Professor of Microbiology at the University of
Pennsylvania, and scientific director at Advaxis, a publicly traded
biotechnology company located in Princeton, presented evidence of the cancer-
fighting properties of a live modified Listeria cancer vaccine she created.
The vaccine successfully eradicated several types of rapidly growing cancers
in mice.
The ability of Listeria vaccines to stimulate the body's immune responses
has been known for some time, and Dr. Paterson's findings about the actions of
Listeria is the result of more than ten years of scientific research and over
100 published studies in this field.
Dr. Paterson found when Listeria is introduced in the body, it has an
extremely powerful, direct stimulatory effect on the activities of tumor-
killing T cells. "Essentially, modified Listeria vaccines harness the power of
the immune system against this infectious agent, and then directs it to
successfully attack cancer cells," explains Dr. John Rothman, Advaxis' Vice
President of clinical development. "The vaccines teach the immune system to
mount a specialized, targeted response that is lethal to cancer."
Advaxis is now undertaking preliminary trials for two new proprietary
cancer-fighting vaccines: Lovaxin B, for the treatment of breast cancer and
Lovaxin-C for cervical cancer. Although these are early results, clinical
trials are expected to begin within the next year to two years.
Says Dr. Rothman: "If Lovaxin C is successful in clinical trials it has
the potential for treating cervical cancer in early and late stage disease,
including those women who have positive pap smears and currently require
surgery."
Cervical cancer affects many thousands of women each year. The newly
developed vaccine therapies for cervical cancer are directed at those women
who have not been exposed to HPV, the viral cause of cervical cancer. Lovaxin
C, which will be entering Phase I/II clinical trials, is intended to cure
women who have already cervical cancer as a result of HPV exposure.
For more information, log onto advaxis.com.
SOURCE Advaxis
Web Site: advaxis.com
prnewswire.com. |
